The Food and Drug Administration is on a roll. America’s drug regulator recently approved Veopoz as the first treatment for Chaple disease, a very rare inherited immune condition. The FDA also gave full approval to a drug called Leqembi, which slowed Alzheimer’s patients’ functional and cognitive decline by 27% over 18 months, according to trial data. And agency officials green-lit the first vaccine to protect infants from respiratory syncytial virus.
United-states
America
Drug-administration
Y-mabs-therapeutics
Milbank-quarterly
Fda
Drugs
Healthcare
Innovation
Regulation